Can You Get a THC:CBD Spray on the NHS for MS Spasticity?

If you or someone you care about has multiple sclerosis (MS) and struggles with moderate to severe spasticity, you might have heard about cannabis-based medicines like THC:CBD sprays. These treatments offer hope for symptom relief when other options fall short. But can you actually get a THC:CBD spray on the NHS? This post explains the current situation, what changed in 2018, the rules around prescribing, and how cost and licensing affect access.

Understanding MS Spasticity and THC:CBD Sprays

Spasticity is a common MS symptom that causes muscle stiffness and involuntary spasms, making daily movements painful or difficult. Traditional muscle relaxants don’t always work well for everyone. That’s where cannabis-based medicines come in.

THC:CBD sprays are oral sprays containing specific ratios of two cannabinoids:

THC (tetrahydrocannabinol) – the psychoactive component providing muscle relaxation
CBD (cannabidiol) – non-psychoactive, thought to modulate THC’s effects and have anti-inflammatory properties

The most commonly prescribed THC:CBD spray in the UK is nabiximols, sold under the brand name Sativex.

The 2018 Rescheduling: What Changed?

Before 2018, cannabis-based products were classified in a way that made prescribing them very restrictive. In November 2018, UK authorities rescheduled cannabis-based medicines, officially classifying products like Sativex as controlled drugs that specialist doctors can prescribe legally.

What this rescheduling meant in practice:

Specialist doctors gained the legal authority to prescribe cannabis-based medicines like THC:CBD sprays for MS spasticity and other approved indications.
Patients could access these medicines through pharmacies with a valid prescription, provided by specialists.
However, having legal prescribability did not guarantee NHS funding or availability.

In simple terms: since 2018, it's legal for specialists to prescribe THC:CBD sprays in the UK, including on the NHS — but that doesn’t mean you will automatically get the spray funded.

NHS Funding vs Legal Prescribing: What’s the Difference?

Here is where confusion often creeps in. Just because a medicine is licensed and legal to prescribe does not mean the NHS has agreed to routinely pay for it.

Aspect Legal Prescribing NHS Funding Definition Specialist doctors can legally write a prescription for the medicine. The NHS agrees to pay for the medicine as part of routine care. Prescribing Responsibility Usually specialist consultants experienced in MS and spasticity management. Determined by Clinical Commissioning Groups (CCGs), Integrated Care Boards (ICBs), or NHS England guidance. Availability to Patients Possible via private prescription or NHS prescription if funded. Only if the local NHS service or national guidance approves funding.

Sativex (THC:CBD spray) is licensed in the UK for treating moderate to severe MS spasticity in patients who have not responded well to other drugs. Yet NHS funding decisions are more complex.

Specialist-Only Prescribing Rules

Because of the controlled drug status and specialist nature of MS spasticity treatment, only qualified neurologists or MS specialists can initiate and manage THC:CBD spray treatment. GPs or general neurologists not specialising in MS typically cannot prescribe it.

Specialist prescribing means:

Assessment of other treatments first
Starting a four-week trial of the THC:CBD spray to see if the patient experiences clinically significant improvement
Close monitoring and follow-up during the trial

The four-week THC:CBD spray trial is an important NHS protocol step. Patients use the spray for 4 weeks and their specialist evaluates whether spasticity has improved meaningfully. If yes, treatment can continue; if not, it is usually discontinued.

NHS Funding Realities: Why Access Remains Difficult

Despite being legal to prescribe, the reality is NHS funding for THC:CBD sprays like Sativex is inconsistent and quite restricted:

NICE Guidance: The National Institute for Health and Care Excellence (NICE) gave preliminary positive guidance on Sativex but advised limited use due to cost-effectiveness concerns. As a result, many local NHS bodies opted not to fund the spray routinely.
Local Variations: Some Clinical Commissioning Groups (CCGs) or Integrated Care Boards have placed strict criteria, or refuse funding altogether, meaning access depends on your location.
Individual Funding Requests: Patients may try to secure funding via individual requests, which can be time-consuming and not guaranteed.

In summary, NHS access to THC:CBD sprays for MS spasticity is a postcode lottery influenced by cost, budget pressures, and local clinical policies.

Unlicensed Cannabis-Based Medicines and NHS Caution

Not all cannabis-based treatments carry a licence like Sativex. Many products available on the private market are unlicensed. These include oils, tinctures, capsules, and other formulations promoted for MS symptoms.

NHS professionals approach unlicensed cannabis-based medicines with caution because:

There is limited robust clinical trial evidence supporting their effectiveness or safety in MS spasticity.
NHS funding is almost never available for unlicensed products.
Prescribing unlicensed medicines requires specialist clinical judgement and usually only happens when licensed options fail.

Patients seeking unlicensed options often pay privately and should seek reputable clinics and advice — platforms like medicalcannabis.co.uk can help locate UK clinics specialising in this area.

Releaf.co.uk Explainer

For a patient-friendly breakdown of cannabis-based medicines, licensing, prescribing rules, and what to expect during treatment, releaf.co.uk offers helpful guides and resources.

Price Considerations: What About the Cost?

No specific prices for THC:CBD sprays like Sativex were directly stated in publicly available NHS documents we reviewed. Prices can vary due to pharmacy markups and dispensing fees.

Generally, private prescriptions for Sativex can cost several hundred pounds per month. If your treatment is NHS-funded, you typically pay only the standard NHS prescription charge (or nothing if exempt).

If exact pricing from future sources becomes available, it should be quoted exactly with clear attribution due to regional variation and potential commercial confidentiality.

Summary: What Does This Mean for Patients?

To translate all this into practical terms:

Since 2018, THC:CBD sprays like Sativex are legal for specialists to prescribe for moderate to severe MS spasticity.
You need to see an MS specialist who can start a four-week trial and judge treatment success.
NHS funding for this therapy is not guaranteed and varies by region.
If funding is not available, the treatment can only be accessed privately, which can be costly.
Unlicensed cannabis-based products remain mostly unavailable on the NHS and are approached cautiously by doctors.
Reliable online platforms like medicalcannabis.co.uk and releaf.co.uk can help you navigate options and find specialist clinics.

Final Thoughts

Accessing a THC:CBD spray on the NHS for MS spasticity is not straightforward, despite legal prescribing post-2018. The key hurdle remains funding — while the medicine itself is licensed and medically recognized, not all NHS areas have agreed to pay for it. If you think this treatment might help you, speak first to your MS specialist or neurologist and ask if you might be a candidate for a four-week trial under their care. Be aware of the funding limitations and prepare to explore private options if needed.

Keeping up to date with policy changes, NICE guidance updates, and local NHS formularies is important. I'll continue https://smoothdecorator.com/how-can-i-spot-overconfident-medical-cannabis-marketing-in-the-uk/ to monitor this evolving medical cannabis for anxiety uk landscape and report changes that could improve access for people managing MS spasticity.